Psychedelics Feature During Congressional Ways and
Post# of 137
(Total Views: 197)
Posted On: 09/28/2022 5:44:43 PM
Psychedelics Feature During Congressional Ways and Means Committee Meeting
Last week, Rep. Earl Blumenauer discussed the therapeutic potential of psychedelic drugs as alternatives to traditional drugs for mental health disorders during a House Ways and Means Committee meeting. During the meeting, legislators talked about proposals on family and worker access to health support.
The congressman stated that while he was encouraged by how legislators were moving forward with integrating various reform areas, including outpatient care, there was still a need to advance the search for therapies that could help to better manage mental health conditions; he proposed that psychedelics be included in the healthcare improvements discussion. His statement was made in response to the committee’s discussion.
This isn’t the first time the congressman has highlighted the benefits of psychedelics. Earlier in January, Blumenauer cowrote a bipartisan letter asking that the Drug Enforcement Administration permit patients with terminal illnesses to have access to psilocybin under federal Right-to-Try laws.
This move was supported by a bicameral and bipartisan congressional effort, which reaffirmed the Right-to-Try statute affording these patients access to drugs classified under Schedule I, including psychedelic substances such as psilocybin and cannabis. Other initiatives focusing on psychedelic substances include a recent spending bill and approved amendments to a defense legislation calling for federal agencies to further support research into the therapeutic potential of psychedelic drugs.
Some of the most recent advanced psychedelic reform introducers include the following: Rep. Earl Blumenauer, Rep. Alexandria Ocasio-Cortez, Sen. Brian Schatz and Sen. Cory Booker, all Democrats; and Rep. Nancy Mace, Rep. Matt Gaetz, Sen. Dan Crenshaw and Sen. Rand Paul, all Republicans.
Despite the growing national trend toward psychedelics reform, some legislators feel that Congress still has a long way to go, regardless of what science and public opinion says. It doesn’t help that federal interest isn’t keeping up with the discussion at the state level either.
Rep. Jared Huffman, a supporter of psychedelics reform, stated recently that he believed that natural fungi and plants such as psilocybin held great benefits when utilized in the appropriate setting; he also noted that it was backward and embarrassing how slow some federal legislators were in approaching the issue because they held outdated views on the subject. Huffman explained that evidence from recently conducted studies had shown that psychedelics could be a game changer.
Thus far, studies have found that psilocybin may be useful in managing treatment-resistant depression while MDMA may be effective in the treatment of post-traumatic stress disorder. Companies such as Silo Pharma Inc. (OTC: SILOD) are also conducting their own R&D programs on different psychedelics, so it wouldn’t be surprising if more therapeutic uses of various compounds such as psilocybin are documented.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTC: SILOD) are available in the company’s newsroom at https://ibn.fm/SILO
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Last week, Rep. Earl Blumenauer discussed the therapeutic potential of psychedelic drugs as alternatives to traditional drugs for mental health disorders during a House Ways and Means Committee meeting. During the meeting, legislators talked about proposals on family and worker access to health support.
The congressman stated that while he was encouraged by how legislators were moving forward with integrating various reform areas, including outpatient care, there was still a need to advance the search for therapies that could help to better manage mental health conditions; he proposed that psychedelics be included in the healthcare improvements discussion. His statement was made in response to the committee’s discussion.
This isn’t the first time the congressman has highlighted the benefits of psychedelics. Earlier in January, Blumenauer cowrote a bipartisan letter asking that the Drug Enforcement Administration permit patients with terminal illnesses to have access to psilocybin under federal Right-to-Try laws.
This move was supported by a bicameral and bipartisan congressional effort, which reaffirmed the Right-to-Try statute affording these patients access to drugs classified under Schedule I, including psychedelic substances such as psilocybin and cannabis. Other initiatives focusing on psychedelic substances include a recent spending bill and approved amendments to a defense legislation calling for federal agencies to further support research into the therapeutic potential of psychedelic drugs.
Some of the most recent advanced psychedelic reform introducers include the following: Rep. Earl Blumenauer, Rep. Alexandria Ocasio-Cortez, Sen. Brian Schatz and Sen. Cory Booker, all Democrats; and Rep. Nancy Mace, Rep. Matt Gaetz, Sen. Dan Crenshaw and Sen. Rand Paul, all Republicans.
Despite the growing national trend toward psychedelics reform, some legislators feel that Congress still has a long way to go, regardless of what science and public opinion says. It doesn’t help that federal interest isn’t keeping up with the discussion at the state level either.
Rep. Jared Huffman, a supporter of psychedelics reform, stated recently that he believed that natural fungi and plants such as psilocybin held great benefits when utilized in the appropriate setting; he also noted that it was backward and embarrassing how slow some federal legislators were in approaching the issue because they held outdated views on the subject. Huffman explained that evidence from recently conducted studies had shown that psychedelics could be a game changer.
Thus far, studies have found that psilocybin may be useful in managing treatment-resistant depression while MDMA may be effective in the treatment of post-traumatic stress disorder. Companies such as Silo Pharma Inc. (OTC: SILOD) are also conducting their own R&D programs on different psychedelics, so it wouldn’t be surprising if more therapeutic uses of various compounds such as psilocybin are documented.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTC: SILOD) are available in the company’s newsroom at https://ibn.fm/SILO
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
(0)
(0)